| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| J0584 |
Injection, burosumab-twza 1 mg |
3,527 |
2,333 |
$72.39M |
| J0638 |
Injection, canakinumab, 1 mg |
910 |
793 |
$19.84M |
| J1726 |
Injection, hydroxyprogesterone caproate, (makena), 10 mg |
6,489 |
5,149 |
$18.63M |
| J7170 |
Injection, emicizumab-kxwh, 0.5 mg |
763 |
439 |
$16.59M |
| J3285 |
Injection, treprostinil, 1 mg |
2,757 |
1,496 |
$11.52M |
| J7298 |
Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg |
11,978 |
11,001 |
$10.75M |
| J2357 |
Injection, omalizumab, 5 mg |
3,752 |
2,935 |
$10.02M |
| J7307 |
Etonogestrel (contraceptive) implant system, including implant and supplies |
9,188 |
8,531 |
$8.28M |
| J2323 |
Injection, natalizumab, 1 mg |
859 |
812 |
$6.46M |
| J2182 |
Injection, mepolizumab, 1 mg |
1,744 |
1,538 |
$5.50M |
| J3380 |
Injection, vedolizumab, intravenous, 1 mg |
705 |
645 |
$5.34M |
| J1950 |
Injection, leuprolide acetate (for depot suspension), per 3.75 mg |
1,047 |
952 |
$5.06M |
| J0490 |
Injection, belimumab, 10 mg |
1,342 |
1,227 |
$4.85M |
| J0585 |
Injection, onabotulinumtoxina, 1 unit |
4,142 |
3,922 |
$4.45M |
| J2350 |
Injection, ocrelizumab, 1 mg |
137 |
133 |
$4.30M |
| J0178 |
Injection, aflibercept, 1 mg |
1,338 |
1,314 |
$3.65M |
| J2315 |
Injection, naltrexone, depot form, 1 mg |
2,144 |
2,035 |
$2.92M |
| J0775 |
Injection, collagenase, clostridium histolyticum, 0.01 mg |
271 |
240 |
$2.67M |
| 90378 |
|
838 |
551 |
$2.00M |
| J2426 |
Injection, paliperidone palmitate extended release (invega sustenna), 1 mg |
585 |
523 |
$1.20M |
| J0517 |
Injection, benralizumab, 1 mg |
252 |
227 |
$1.18M |
| Q9992 |
Injection, buprenorphine extended-release (sublocade), greater than 100 mg |
612 |
518 |
$1.11M |
| J0180 |
Injection, agalsidase beta, 1 mg |
51 |
36 |
$1.07M |
| Q9991 |
Injection, buprenorphine extended-release (sublocade), less than or equal to 100 mg |
520 |
431 |
$930K |
| J0897 |
Injection, denosumab, 1 mg |
478 |
457 |
$802K |
| J3590 |
Unclassified biologics |
111 |
77 |
$709K |
| J2356 |
Injection, tezepelumab-ekko, 1 mg |
191 |
151 |
$661K |
| J7296 |
Levonorgestrel-releasing intrauterine contraceptive system, (kyleena), 19.5 mg |
700 |
671 |
$637K |
| J0401 |
Injection, aripiprazole (abilify maintena), 1 mg |
309 |
290 |
$621K |
| Q5103 |
Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg |
103 |
99 |
$493K |
| J7301 |
Levonorgestrel-releasing intrauterine contraceptive system (skyla), 13.5 mg |
522 |
472 |
$374K |
| J0741 |
Injection, cabotegravir and rilpivirine, 2mg/3mg |
59 |
57 |
$353K |
| J0578 |
Injection, buprenorphine extended release (brixadi), greater than 7 days and up to 28 days of therapy |
185 |
168 |
$323K |
| J1745 |
Injection, infliximab, excludes biosimilar, 10 mg |
42 |
39 |
$238K |
| J3357 |
Ustekinumab, for subcutaneous injection, 1 mg |
13 |
13 |
$236K |
| Q5104 |
Injection, infliximab-abda, biosimilar, (renflexis), 10 mg |
59 |
55 |
$220K |
| J3490 |
Unclassified drugs |
52 |
50 |
$126K |
| J2794 |
Injection, risperidone (risperdal consta), 0.5 mg |
109 |
91 |
$126K |
| Q0513 |
Pharmacy dispensing fee for inhalation drug(s); per 30 days |
418 |
365 |
$95K |
| J1561 |
Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg |
30 |
27 |
$86K |
| J0577 |
Injection, buprenorphine extended-release (brixadi), less than or equal to 7 days of therapy |
109 |
63 |
$65K |
| J0491 |
Injection, anifrolumab-fnia, 1 mg |
12 |
12 |
$56K |
| S9379 |
Home infusion therapy, infusion therapy, not otherwise classified; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem |
213 |
183 |
$48K |
| J7518 |
Mycophenolic acid, oral, 180 mg |
1,330 |
1,086 |
$44K |
| J7507 |
Tacrolimus, immediate release, oral, 1 mg |
4,401 |
3,363 |
$40K |
| A4222 |
Infusion supplies for external drug infusion pump, per cassette or bag (list drugs separately) |
532 |
358 |
$37K |
| Q0512 |
Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period |
9,745 |
4,901 |
$37K |
| J7517 |
Mycophenolate mofetil, oral, 250 mg |
2,610 |
2,235 |
$31K |
| 99601 |
|
181 |
65 |
$27K |
| J1559 |
Injection, immune globulin (hizentra), 100 mg |
90 |
57 |
$24K |
| Q0511 |
Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period |
1,793 |
1,547 |
$14K |
| J2790 |
Injection, rho d immune globulin, human, full dose, 300 micrograms (1500 i.u.) |
153 |
128 |
$14K |
| A4221 |
Supplies for maintenance of non-insulin drug infusion catheter, per week (list drugs separately) |
412 |
278 |
$12K |
| K0455 |
Infusion pump used for uninterrupted parenteral administration of medication, (e.g., epoprostenol or treprostinol) |
385 |
332 |
$10K |
| J7515 |
Cyclosporine, oral, 25 mg |
378 |
333 |
$6K |
| J7520 |
Sirolimus, oral, 1 mg |
52 |
50 |
$3K |
| S9357 |
Home infusion therapy, enzyme replacement intravenous therapy; (e.g., imiglucerase); administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem |
95 |
78 |
$3K |
| J7699 |
Noc drugs, inhalation solution administered through dme |
28 |
28 |
$3K |
| S5000 |
Prescription drug, generic |
112 |
89 |
$2K |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
928 |
831 |
$881.68 |